What is IDRx?
IDRx is dedicated to advancing cancer treatment through the development of precision therapies. The company's core mission is to overcome the limitations of current precision cancer medicines by creating highly potent and selective targeted therapies. These therapies are designed to disrupt key tumor escape mechanisms, thereby prolonging patient response to treatment and improving outcomes in oncology.
How much funding has IDRx raised?
IDRx has raised a total of $242M across 2 funding rounds:
Series A
$122M
Series B
$120M
Series A (2022): $122M with participation from Forge Life Science Partners, Andreessen Horowitz, Nextech Invest, and Casdin Capital
Series B (2024): $120M led by RA Capital Management and Commodore Capital
Key Investors in IDRx
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. They aim to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
Commodore Capital
Commodore Capital focuses on investing in innovative biopharmaceutical companies that aim to improve patients' lives. They partner with smaller companies to support the development of new, safe, and effective medicines, facilitating the translation of scientific discoveries into clinical breakthroughs.
Forge Life Science Partners
Forge Life Science Partners is an investor in the Series A round, indicating a focus on supporting early-stage life science innovation and the development of new therapeutic modalities.
What's next for IDRx?
With substantial backing from major investors, IDRx is poised for accelerated growth and development. The recent Series B financing, following a significant Series A round, suggests the company is entering a critical scaling phase. This strategic capital will likely be deployed to advance its pipeline of precision therapies through clinical trials, expand its research and development capabilities, and potentially prepare for future commercialization efforts. The company's focus on addressing tumor escape mechanisms positions it to make a significant impact in the precision oncology landscape.
See full IDRx company page
